Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 3905240, 8 pages
http://dx.doi.org/10.1155/2016/3905240
Review Article

The Role of Genetic and Immune Factors for the Pathogenesis of Primary Sclerosing Cholangitis in Childhood

1Department of Pediatrics, UFMG, 30130-100 Belo Horizonte, MG, Brazil
2Instituto Nacional de Ciência e Tecnologia de Medicina Molecular, INCT-MM, CNPq-FAPEMIG, Universidade Federal de Minas Gerais, 30130-100 Belo Horizonte, MG, Brazil
3Laboratório Interdisciplinar de Investigação Médica, Avenida Alfredo Balena 190, 2nd Floor, Room 281, 30130-100 Belo Horizonte, MG, Brazil

Received 5 May 2016; Accepted 16 October 2016

Academic Editor: Antonios Athanasiou

Copyright © 2016 Priscila Menezes Ferri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. M. Hirschfield, T. H. Karlsen, K. D. Lindor, and D. H. Adams, “Primary sclerosing cholangitis,” The Lancet, vol. 382, no. 9904, pp. 1587–1599, 2013. View at Publisher · View at Google Scholar
  2. R. W. G. Chapman, B. A. M. Arborgh, J. M. Rhodes et al., “Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology,” Gut, vol. 21, no. 10, pp. 870–877, 1980. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Schrumpf and K. M. Boberg, “Epidemiology of primary sclerosing cholangitis,” Best Practice and Research: Clinical Gastroenterology, vol. 15, no. 4, pp. 553–562, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. J. E. Eaton, J. A. Talwalkar, K. N. Lazaridis, G. J. Gores, and K. D. Lindor, “Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management,” Gastroenterology, vol. 145, no. 3, pp. 521–536, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Singh and J. A. Talwalkar, “Primary sclerosing cholangitis: diagnosis, prognosis, and management,” Clinical Gastroenterology and Hepatology, vol. 11, no. 8, pp. 898–907, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Gohlke, A. W. Lohse, H. P. Dienes et al., “Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis,” Journal of Hepatology, vol. 24, no. 6, pp. 699–705, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. G. V. Gregorio, B. Portmann, J. Karani et al., “Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study,” Hepatology, vol. 33, no. 3, pp. 544–553, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Chapman, J. Fevery, A. Kalloo et al., “Diagnosis and management of primary sclerosing cholangitis,” Hepatology, vol. 51, no. 2, pp. 660–678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Gotthardt and A. Stiehl, “Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis,” Clinics in Liver Disease, vol. 14, no. 2, pp. 349–358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Dave, B. J. Elmunzer, B. A. Dwamena, and P. D. R. Higgins, “Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography,” Radiology, vol. 256, no. 2, pp. 387–396, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Ahrar, M. S. Jafarpishe, A. Hekmatnia, R. Solouki, and M. H. Emami, “Magnetic resonance cholangiography compared with endoscopic retrograde cholangiography in the diagnosis of primary sclerosing cholangitis,” Journal of Research in Medical Sciences, vol. 19, no. 12, pp. 1150–1154, 2014. View at Google Scholar · View at Scopus
  12. J. R. Hov, K. M. Boberg, and T. H. Karlsen, “Autoantibodies in primary sclerosing cholangitis,” World Journal of Gastroenterology, vol. 14, no. 24, pp. 3781–3791, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Terjung, V. Herzog, H. J. Worman et al., “Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins,” Hepatology, vol. 28, no. 2, pp. 332–340, 1998. View at Publisher · View at Google Scholar
  14. E. Liaskou, G. M. Hirschfield, and M. E. Gershwin, “Mechanisms of tissue injury in autoimmune liver diseases,” Seminars in Immunopathology, vol. 36, no. 5, pp. 553–568, 2014. View at Publisher · View at Google Scholar
  15. A. K. Lunder, J. R. Hov, A. Borthne et al., “Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease,” Gastroenterology, vol. 151, no. 4, pp. 660–669.e4, 2016. View at Publisher · View at Google Scholar
  16. B. Terjung, J. Söhne, B. Lechtenberg et al., “p-ANCAs in autoimmune liver disorders recognise human β-tubulin isotype 5 and cross-react with microbial protein FtsZ,” Gut, vol. 59, no. 6, pp. 808–816, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. T. Jendrek, D. Gotthardt, T. Nitzsche et al., “Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis,” Gut, 2016. View at Publisher · View at Google Scholar
  18. G. Maggiore, S. Riva, and M. Sciveres, “Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood,” Minerva Gastroenterologica e Dietologica, vol. 55, no. 1, pp. 53–70, 2009. View at Google Scholar · View at Scopus
  19. U. Broomé, R. Olsson, L. Lööf et al., “Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis,” Gut, vol. 38, no. 4, pp. 610–615, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. T. R. Card, M. Solaymani-Dodaran, and J. West, “Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study,” Journal of Hepatology, vol. 48, no. 6, pp. 939–944, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Olsson, K. M. Boberg, O. S. de Muckadell et al., “High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study,” Gastroenterology, vol. 129, no. 5, pp. 1464–1472, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. K. D. Lindor, K. V. Kowdley, V. A. C. Luketic et al., “High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis,” Hepatology, vol. 50, no. 3, pp. 808–814, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. L. Bowlus, “Cutting edge issues in primary sclerosing cholangitis,” Clinical Reviews in Allergy and Immunology, vol. 41, no. 2, pp. 139–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Bergquist, G. Lindberg, S. Saarinen, and U. Broomé, “Increased prevalence of primary sclerosing cholangitis among first-degree relatives,” Journal of Hepatology, vol. 42, no. 2, pp. 252–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. T. H. Karlsen, A. Franke, E. Melum et al., “Genome-wide association analysis in primary sclerosing cholangitis,” Gastroenterology, vol. 138, no. 3, pp. 1102–1111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Melum, A. Franke, C. Schramm et al., “Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci,” Nature Genetics, vol. 43, no. 1, pp. 17–19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Folseraas, E. Melum, P. Rausch et al., “Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci,” Journal of Hepatology, vol. 57, no. 2, pp. 366–375, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Srivastava, G. F. Mells, H. J. Cordell et al., “Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis,” Scandinavian Journal of Gastroenterology, vol. 47, no. 7, pp. 820–826, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Z. Liu, J. R. Hov, T. Folseraas et al., “Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis,” Nature Genetics, vol. 45, no. 6, pp. 670–675, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Spurkland, S. Saarinen, K. M. Boberg et al., “HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations,” Tissue Antigens, vol. 53, no. 5, pp. 459–469, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. P. T. Donaldson and S. Norris, “Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis,” Autoimmunity, vol. 35, no. 8, pp. 555–564, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. Farrant, D. G. Doherty, P. T. Donaldson et al., “Amino acid substitutions at position 38 of the DRβ polypeptide confer susceptibility to and protection from primary sclerosing cholangitis,” Hepatology, vol. 16, no. 2, pp. 390–395, 1992. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Amar, C. Brautbar, E. Goldin et al., “Serological and molecular analysis of HLA in Israeli primary sclerosing cholangitis patients,” European Journal of Immunogenetics, vol. 19, no. 5, pp. 295–302, 1992. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Olerup, R. Olsson, R. Hultcrantz, and U. Broomé, “HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis,” Gastroenterology, vol. 108, no. 3, pp. 870–878, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. M. H. K. Leidenius, S. A. Koskimies, I. H. Kellokumpu, and K. A. V. Hockerstedt, “HLA antigens in ulcerative colitis and primary sclerosing cholangitis,” APMIS, vol. 103, no. 7-8, pp. 519–524, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Wilschanski, P. Chait, J. A. Wade et al., “Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis,” Hepatology, vol. 22, no. 5, pp. 1415–1422, 1995. View at Publisher · View at Google Scholar · View at Scopus
  37. K. M. Boberg, A. Spurkland, G. Rocca et al., “The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis,” Scandinavian Journal of Gastroenterology, vol. 36, no. 8, pp. 886–890, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. P. L. Bittencourt, S. A. Palacios, E. L. Cançado et al., “Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB113 but not with tumour necrosis factor α-308 promoter polymorphism,” Gut, vol. 51, no. 4, pp. 609–610, 2002. View at Publisher · View at Google Scholar
  39. T. M. Neri, G. M. Cavestro, P. Seghini et al., “Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population,” Digestive and Liver Disease, vol. 35, no. 8, pp. 571–576, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. J. R. Hov, A. Lleo, C. Selmi et al., “Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C,” Journal of Hepatology, vol. 52, no. 5, pp. 712–717, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Wang, H. Su, J. Underhill et al., “Autoantibody and human leukocyte antigen profiles in children with autoimmune liver disease and their first-degree relatives,” Journal of Pediatric Gastroenterology and Nutrition, vol. 58, no. 4, pp. 457–462, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Næss, B. A. Lie, E. Melum et al., “Refinement of the MHC risk map in a Scandinavian primary sclerosing cholangitis population,” PLoS ONE, vol. 9, no. 12, Article ID e114486, 2014. View at Publisher · View at Google Scholar
  43. K. Wiencke, T. H. Karlsen, K. M. Boberg et al., “Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes,” Tissue Antigens, vol. 69, no. 2, pp. 161–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. T. H. Karlsen, K. M. Boberg, M. Olsson et al., “Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis,” Journal of Hepatology, vol. 46, no. 5, pp. 899–906, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Norris, E. Kondeatis, R. Collins et al., “Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism,” Gastroenterology, vol. 120, no. 6, pp. 1475–1482, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. G. F. Mells, A. Kaser, and T. H. Karlsen, “Novel insights into autoimmune liver diseases provided by genome-wide association studies,” Journal of Autoimmunity, vol. 46, pp. 41–54, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. C. A. O'Mahony and J. M. Vierling, “Etiopathogenesis of primarysclerosing cholangitis,” Seminars of Liver Diseases, vol. 26, pp. 3–21, 2006. View at Google Scholar
  48. B. Xu, U. Broomé, B.-G. Ericzon, and S. Sumitran-Holgersson, “High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6,” Gut, vol. 51, no. 1, pp. 120–127, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Karrar, U. Broomé, T. Södergren et al., “Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis,” Gastroenterology, vol. 132, no. 4, pp. 1504–1514, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. S. P. O'Hara, P. L. Splinter, C. E. Trussoni, G. B. Gajdos, P. N. Lineswala, and N. F. LaRusso, “Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation,” The Journal of Biological Chemistry, vol. 286, no. 35, pp. 30352–30360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Hashimoto, K. D. Lindor, H. A. Homburger et al., “Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis,” Mayo Clinic Proceedings, vol. 68, no. 11, pp. 1049–1055, 1993. View at Publisher · View at Google Scholar · View at Scopus
  52. T. L. Whiteside, S. Lasky, L. Si, and D. H. Van Thiel, “Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis,” Hepatology, vol. 5, no. 3, pp. 468–474, 1985. View at Publisher · View at Google Scholar · View at Scopus
  53. J. A. Snook, R. W. Chapman, G. K. Sachdev et al., “Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis,” Journal of Hepatology, vol. 9, no. 1, pp. 36–41, 1989. View at Publisher · View at Google Scholar · View at Scopus
  54. J.-P. Coppé, C. K. Patil, F. Rodier et al., “Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor,” PLoS Biology, vol. 6, no. 12, article e301, pp. 2853–2868, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. J. H. Tabibian, S. P. O'Hara, P. L. Splinter, C. E. Trussoni, and N. F. Larusso, “Cholangiocyte senescence by way of N-Ras activation is a characteristic of primary sclerosing cholangitis,” Hepatology, vol. 59, no. 6, pp. 2263–2275, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Panasiuk, D. Prokopowicz, J. Zak, B. Panasiuk, and J. Wysocka, “Lymphocyte subpopulations in peripheral blood in primary sclerosing cholangitis,” Hepato-Gastroenterology, vol. 51, no. 59, pp. 1289–1291, 2004. View at Google Scholar · View at Scopus
  57. X. Bo, U. Broomé, M. Remberger, and S. Sumitran-Holgersson, “Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis,” Gut, vol. 49, no. 1, pp. 131–141, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Exley, J. Garcia, S. B. Wilson et al., “CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes,” Immunology, vol. 100, no. 1, pp. 37–47, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Schrumpf, C. Tan, T. H. Karlsen et al., “The biliary epithelium presents antigens to and activates natural killer T cells,” Hepatology, vol. 62, no. 4, pp. 1249–1259, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Eksteen, A. J. Grant, A. Miles et al., “Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis,” The Journal of Experimental Medicine, vol. 200, no. 11, pp. 1511–1517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. A. J. Grant, P. F. Lalor, S. G. Hübscher, M. Briskin, and D. H. Adams, “MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease),” Hepatology, vol. 33, no. 5, pp. 1065–1072, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Miles, E. Liaskou, B. Eksteen, P. F. Lalor, and D. H. Adams, “CCL25 and CCL28 promote α4β7-integrin- dependent adhesion of lymphocytes to MAdCAM-1 under shear flow,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 294, no. 5, pp. G1257–G1267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Neumann, N. Kruse, B. Szilagyi et al., “Connecting liver and gut: murine liver sinusoidal endothelium induces gut tropism of CD4+ T cells via retinoic acid,” Hepatology, vol. 55, no. 6, pp. 1976–1984, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. E. B. G. Martins, A. K. Graham, R. W. Chapman, and K. A. Fleming, “Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases,” Hepatology, vol. 23, no. 5, pp. 988–993, 1996. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Sebode, M. Peiseler, B. Franke et al., “Reduced FOXP3+ regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms,” Journal of Hepatology, vol. 60, no. 5, pp. 1010–1016, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Katt, D. Schwinge, T. Schoknecht et al., “Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis,” Hepatology, vol. 58, no. 3, pp. 1084–1093, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. T. H. Karlsen, E. Schrumpf, and K. M. Boberg, “Genetic epidemiology of primary sclerosing cholangitis,” World Journal of Gastroenterology, vol. 13, no. 41, pp. 5421–5431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Eri, J. R. Jonsson, N. Pandeya et al., “CCR5-Δ32 mutation is strongly associated with primary sclerosing cholangitis,” Genes & Immunity, vol. 5, no. 6, pp. 444–450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Melum, T. H. Karlsen, U. Broomé et al., “The 32-base pair deletion of the chemokine receptor 5 gene (CCR5-Δ32) is not associated with primary sclerosing cholangitis in 363 Scandinavian patients,” Tissue Antigens, vol. 68, no. 1, pp. 78–81, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. X. Yang, S. N. Cullen, J. H. Li, R. W. Chapman, and D. P. Jewell, “Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1,” Journal of Hepatology, vol. 40, no. 3, pp. 375–379, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Nakamura, K. Honda, T. Mizutani, H. Akiho, and N. Harada, “Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules,” World Journal of Gastroenterology, vol. 12, no. 29, pp. 4628–4635, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. E. Liaskou, L. E. Jeffery, P. J. Trivedi et al., “Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis,” Gastroenterology, vol. 147, no. 1, pp. 221–232.e7, 2014. View at Publisher · View at Google Scholar · View at Scopus